A strategic framework agreement was signed between a Xiamen-based biomedical company and four other research groups at the 18th National Academic Conference on Viral Hepatitis and Liver Diseases held in Wuhan, Hubei province from Oct 12 to 14.
The agreement is regarding the research on the clinical cure of chronic hepatitis B and the Amoytop Biotech Company from Xiamen, Fujian province is expecting to provide support for these national research by the end of 2020.
According to the conference, as the leading role of the agreement, the third-generation pegylated interferon used to treat chronic hepatitis B is the first of its kind independently developed by China.
It took the Xiamen-based company 14 years to develop the pegylated interferon, which was available on the market in Octobor last year.
The company's clinical trials of treating chronic hepatitis B and chronic hepatitis C have been supported by the Chinese government as special projects of developing major new medicines.
An employee in the Xiamen-based Amoytop Biotech Company shows a foreign visitor how to operate the manufacturing machine in their workshop. [Photo/ xmnn.cn]